Tags

Type your tag names separated by a space and hit enter

Endocannabinoids and the gastrointestinal tract.
J Endocrinol Invest. 2006; 29(3 Suppl):47-57.JE

Abstract

In the past centuries, different preparations of marijuana have been used for the treatment of gastrointestinal (GI) disorders, such as GI pain, gastroenteritis and diarrhea. Delta9-tetrahydrocannabinol (THC; the active component of marijuana), as well as endogenous and synthetic cannabinoids, exert their biological functions on the gastrointestinal tract by activating two types of cannabinoid receptors, cannabinoid type 1 receptor (CB1 receptor) and cannabinoid type 2 receptor (CB2 receptor). While CB1 receptors are located in the enteric nervous system and in sensory terminals of vagal and spinal neurons and regulate neurotransmitter release, CB2 receptors are mostly distributed in the immune system, with a role presently still difficult to establish. Under pathophysiological conditions, the endocannabinoid system conveys protection to the GI tract, eg from inflammation and abnormally high gastric and enteric secretion. For such protective activities, the endocannabinoid system may represent a new promising therapeutic target against different GI disorders, including frankly inflammatory bowel diseases (eg, Crohn's disease), functional bowel diseases (eg, irritable bowel syndrome), and secretion- and motility-related disorders.

Authors+Show Affiliations

Department of Physiological Chemistry, Johannes Gutenberg-University Mainz, 55099 Mainz, Germany. massa@uni-mainz.deNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16751708

Citation

Massa, F, and K Monory. "Endocannabinoids and the Gastrointestinal Tract." Journal of Endocrinological Investigation, vol. 29, no. 3 Suppl, 2006, pp. 47-57.
Massa F, Monory K. Endocannabinoids and the gastrointestinal tract. J Endocrinol Invest. 2006;29(3 Suppl):47-57.
Massa, F., & Monory, K. (2006). Endocannabinoids and the gastrointestinal tract. Journal of Endocrinological Investigation, 29(3 Suppl), 47-57.
Massa F, Monory K. Endocannabinoids and the Gastrointestinal Tract. J Endocrinol Invest. 2006;29(3 Suppl):47-57. PubMed PMID: 16751708.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Endocannabinoids and the gastrointestinal tract. AU - Massa,F, AU - Monory,K, PY - 2006/6/6/pubmed PY - 2006/6/30/medline PY - 2006/6/6/entrez SP - 47 EP - 57 JF - Journal of endocrinological investigation JO - J. Endocrinol. Invest. VL - 29 IS - 3 Suppl N2 - In the past centuries, different preparations of marijuana have been used for the treatment of gastrointestinal (GI) disorders, such as GI pain, gastroenteritis and diarrhea. Delta9-tetrahydrocannabinol (THC; the active component of marijuana), as well as endogenous and synthetic cannabinoids, exert their biological functions on the gastrointestinal tract by activating two types of cannabinoid receptors, cannabinoid type 1 receptor (CB1 receptor) and cannabinoid type 2 receptor (CB2 receptor). While CB1 receptors are located in the enteric nervous system and in sensory terminals of vagal and spinal neurons and regulate neurotransmitter release, CB2 receptors are mostly distributed in the immune system, with a role presently still difficult to establish. Under pathophysiological conditions, the endocannabinoid system conveys protection to the GI tract, eg from inflammation and abnormally high gastric and enteric secretion. For such protective activities, the endocannabinoid system may represent a new promising therapeutic target against different GI disorders, including frankly inflammatory bowel diseases (eg, Crohn's disease), functional bowel diseases (eg, irritable bowel syndrome), and secretion- and motility-related disorders. SN - 0391-4097 UR - https://www.unboundmedicine.com/medline/citation/16751708/Endocannabinoids_and_the_gastrointestinal_tract_ L2 - https://www.lens.org/lens/search?q=citation_id:16751708 DB - PRIME DP - Unbound Medicine ER -